Amil Druzic, Oncology and Radiotherapy Resident at Clinical center University of Sarajevo, shared a post on LinkedIn:
“Our new study, published in Sarajevo Medical Journal demonstrates the significant efficacy of FOLFIRINOX in treating metastatic pancreatic cancer in a real-world setting. Personalized approaches, including genetic profiling, microbiome analysis, and AI integration, offer promising avenues to enhance treatment outcomes and improve quality of life for patients.”
Enhanced Survival Outcomes with FOLFIRINOX in Initial Metastatic Pancreatic Cancer: Single-Center
Authors: Emir Sokolovic et al.
